Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

被引:3
|
作者
Thomann, Robert [1 ]
Zechmann, Stefan [2 ]
Alexander-David, Nicola
Jornayvaz, Francois R. [3 ]
机构
[1] Burgerspital, Solothurn, Switzerland
[2] Univ Zurich, Inst Primary Care, Zurich, Switzerland
[3] Hop Univ Geneve, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland
关键词
insulin glargine 300 U/mL; type; 2; diabetes; real-world; Switzerland; 100; U/ML; TYPE-2; PEOPLE;
D O I
10.2147/DMSO.S252667
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Insulin glargine 300 U/mL (Gla-300; Toujeo (R)) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100. Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5-10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety. Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p<0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p<0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population. Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.
引用
收藏
页码:2359 / 2365
页数:7
相关论文
共 50 条
  • [1] Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo®) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland
    Peter Wiesli
    Marcus Schories
    [J]. Diabetes Therapy, 2018, 9 : 2325 - 2334
  • [2] Improved Glycemic Control with Insulin Glargine 300U/mL (Toujeo®) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland
    Wiesli, Peter
    Schories, Marcus
    [J]. DIABETES THERAPY, 2018, 9 (06) : 2325 - 2334
  • [3] THE REAL-WORLD DOSE DIFFERENCES OF INSULIN GLARGINE 300 U/ML IN FINLAND
    Koski, L.
    Hahl, J.
    Kaye, S.
    Pousar, K.
    [J]. VALUE IN HEALTH, 2019, 22 : S596 - S596
  • [4] The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real-world data in Israel
    Cohen, Cheli Melzer
    Banon, Tamar
    Shalev, Varda
    Chodick, Gabriel
    [J]. ENDOCRINOLOGY DIABETES & METABOLISM, 2020, 3 (03)
  • [5] Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naive People with Type 2 Diabetes: the ATOS Study
    Galstyan, Gagik R.
    Tirosh, Amir
    Vargas-Uricoechea, Hernando
    Mabunay, Maria Aileen
    Coudert, Mathieu
    Naqvi, Mubarak
    Pilorget, Valerie
    Khan, Niaz
    [J]. DIABETES THERAPY, 2022, 13 (06) : 1187 - 1202
  • [6] Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
    Gagik R. Galstyan
    Amir Tirosh
    Hernando Vargas-Uricoechea
    Maria Aileen Mabunay
    Mathieu Coudert
    Mubarak Naqvi
    Valerie Pilorget
    Niaz Khan
    [J]. Diabetes Therapy, 2022, 13 : 1187 - 1202
  • [7] Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar)
    Pitlick, Jamie M.
    Bryant, Ginelle A.
    Daly, Michael W.
    Koenigsfeld, Carrie F.
    Lehman, Nicholas
    Brueggen, Kaitlin
    McCormick, Alex
    Wellington, Katlynn
    [J]. ANNALS OF PHARMACOTHERAPY, 2020, 54 (09) : 846 - 851
  • [8] Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin
    Fiesselmann, Albrecht
    Wiesner, Tobias
    Fleischmann, Holger
    Bramlage, Peter
    [J]. ACTA DIABETOLOGICA, 2016, 53 (05) : 717 - 726
  • [9] Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin
    Albrecht Fiesselmann
    Tobias Wiesner
    Holger Fleischmann
    Peter Bramlage
    [J]. Acta Diabetologica, 2016, 53 : 717 - 726
  • [10] Effectiveness and safety of insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes after failure of oral therapy in a real-world setting
    Pfohl, Martin
    Jornayvaz, Francois R.
    Fritsche, Andreas
    Pscherer, Stefan
    Anderten, Helmut
    Pegelow, Katrin
    Seufert, Jochen
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (05): : 759 - 766